From Prototypes to Impact: Lessons from FutureHealth Lausanne

Healthcare Innovation & Digitalization are imperative
In order to deal with rising pressures on healthcare systems (costs, aging populations, workforce constraints), digital tools, AI, Big Data, and interoperable systems are now central — not optional. The drive is for systems that are more efficient, accessible, and centred on patient outcomes.

Innovation must move beyond prototypes
The next frontier for health innovation is no longer about creating proofs of concept -  it’s about delivering measurable impact in real-world settings. From integrated care pathways to digital patient records and new health technologies, the focus is shifting toward implementation, scalability, and clinical outcomes. True innovation now means bridging the gap between visionary ideas and solutions that transform everyday healthcare practice.

Oncology remains urgent
The sheer scale of the projected cancer burden (+30 million cases yearly in 2050) underscores the urgent need for scalable, effective diagnostics and therapies globally. As demographics drive incidence upward, progress will depend on earlier detection, broader screening, and personalized treatment pathways that can reduce mortality even when prevention alone cannot.

What does this mean for precision oncology?

Across Switzerland and Europe, there is growing momentum to invest in diagnostic innovation and applied digital health, creating a favorable environment to introduce and scale precision oncology solutions.

To succeed, solutions must show not just technical promise, but clinical translational impact: proof of benefit, real-world outcomes, integration into workflows (clinicians / hospitals).

At the same time, ethical, regulatory, and data infrastructure readiness are non-negotiable. From interoperable patient data and transparent governance to privacy and trust frameworks that enable secure collaboration.

For companies working in functional precision medicine, this context reinforces both market urgency and societal need. Offering solutions that can stratify therapy, reduce overtreatment, and improve outcomes  is not just clinically attractive, but globally essential.